January 06, 2026

Validation of Pathology-AI Integration Tool for Risk Stratification in Locally Advanced Colon Cancer Without Chemotherapy

The Combined Analysis of Pathology and Artificial Intelligence (AI; CAPAI) model effectively stratified patients with colon cancer into distinct prognostic groups, identifying nearly half as low-risk,...

The ASCO Post

November 04, 2025

Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally

Cancer can make its way through the body by shapeshifting through even the narrowest places, like a skilled driver navigating traffic. It has a sly way of adapting to its environment by finding detours around every blockade clinicians place in its path.  

Dana-Farber

August 23, 2022

Gastrointestinal Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner

Key findings from the 2022 ASCO Annual Meeting reveal transformative insights on colorectal cancer treatments, highlighting efficacy disparities and the potential for personalized therapies.

JADPRO

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

August 02, 2023

Gastrointestinal Symptoms May Be Prevalent in Geriatric Female Colorectal Cancer Survivors

About 80% of geriatric female colorectal cancer survivors may experience a range of gastrointestinal symptoms years after receiving a diagnosis and treatment for their tumors, according to a recent st...

The ASCO Post

November 13, 2023

FDA Approves Fruquintinib for Refractory Metastatic Colorectal Cancer

On November 8, the FDA approved an anti-VEGF tyrosine kinase inhibitor for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based che...

The ASCO Post

June 23, 2023

Expert Point of View: Lisa Newman, MD, MPH, FACS, FASCO

Dr. Lisa Newman emphasizes the critical relevance of including diverse populations in clinical genomic profiling for colorectal cancer, shedding light on potential missed opportunities in homogeneous population studies.

The ASCO Post

April 30, 2025

AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash

Compared with a placebo gel, an investigational topical BRAF inhibitor (LUT014) was found to improve the symptoms of acneiform rash in patients with colorectal cancer. These phase II clinical trial re...

The ASCO Post

February 15, 2024

Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?

Circulating tumor DNA may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from receiving adjuvant chemotherapy. The re...

The ASCO Post